Bio

Bio


Dr. Arai has formal training in clinical research with a Masters in Epidemiology from Stanford University. She has a clinical practice seeing all diseases in hematopoietic cell transplantation, with a clinical research focus on the prevention and treatment of post-transplant complications.

Clinical Focus


  • Cancer > Blood and Marrow Transplant
  • Cancer > Hematology
  • Blood and Marrow Transplantation
  • Hematology

Academic Appointments


Honors & Awards


  • “A phase I/II study of post-transplant autologous CIK cells for high-risk hematologic malignancies”, Cancer Treatment Research Foundation (2005-2009)
  • K23-“Reduce GVHD and Relapse using Ex-Vivo Expanded Allogeneic Cell Therapy”, NIH (2003-2008)

Professional Education


  • Medical Education:Dartmouth Geisel School of Medicine (1991) NH
  • Fellowship:Johns Hopkins Hospital (1999) MD
  • Residency:Strong Memorial Hospital (1995) NY
  • Fellowship:Mount Sinai Medical Center (1998) NY
  • Internship:Strong Memorial Hospital (1993) NY
  • MS, Stanford University, Epidemiology (2006)
  • MD, Dartmouth Medical School

Research & Scholarship

Current Research and Scholarly Interests


Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.

Clinical Trials


  • Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Not Recruiting

    The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD free survival at Day 56 post randomization.

    Stanford is currently not accepting patients for this trial. For more information, please contact BMT Referrals, (650) 723 - 0822.

    View full details

  • High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma Not Recruiting

    This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.

    Stanford is currently not accepting patients for this trial. For more information, please contact BMT Referrals, (650) 723 - 0822.

    View full details

  • Transplantation for Patients With Chronic Lymphocytic Leukemia Not Recruiting

    To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

    Stanford is currently not accepting patients for this trial. For more information, please contact BMT Referrals, (650) 723 - 0822.

    View full details

  • Targeted Therapy of Bronchiolitis Obliterans Syndrome Not Recruiting

    This phase II trial studies how well giving fluticasone propionate, azithromycin, and montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans who previously underwent stem cell transplant. FAM may be an effective treatment for bronchiolitis obliterans

    Stanford is currently not accepting patients for this trial. For more information, please contact Physician Referrals, 650-723-0822.

    View full details

  • Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Not Recruiting

    The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.

    Stanford is currently not accepting patients for this trial. For more information, please contact Janice Brown, (650) 723 - 0822.

    View full details

  • Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Not Recruiting

    Acute myeloid leukemia (AML) i